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ABSTRACT
Background: Patients with solid tumors
frequently undergo surgical procedures and
develop procedure-related infections. We
sought to describe the current microbiologic
spectrum of infections at various sites following
common surgical procedures.
Methods: This was a retrospective review of
microbiologic data between January 2011 and
February 2012. The sites studied were those
associated with breast cancer surgery,
thoracotomy, craniotomy, percutaneous
endoscopic gastrostomy (PEG) tube insertion,
and abdominal/pelvic surgery. Only patients
with solid tumors were included.
Results: A total of 368 surgical site infections
(SSIs) were identified (68 breast cancer related;
91 thoracotomy related; 45 craniotomy related;
75 PEG-tube insertion related; and 89
abdominal/pelvic surgery related). Of these,
58% were monomicrobial and 42% were
polymicrobial. Overall, 85% of the 215
monomicrobial infections were caused by
Gram-positive organisms and 13% by Gram-
negative bacilli (GNB). Staphylococcus aureus was
the predominant pathogen in monomicrobial
infections (150 of 215, 70%). Sixty (40%) of
these staphylococcal isolates were methicillin
resistant (MRSA), and 65% had a vancomycin
minimal inhibitory concentration (MIC)
C1.0 lg/ml. Pseudomonas aeruginosa was the
predominant GNB pathogen (19 of 27, 70%).
Staphylococci were also the predominant
pathogens in polymicrobial infections, while
P. aeruginosa and Escherichia coli were the
predominant GNB. Overall, 35% of isolates
from polymicrobial infections were GNB.
Cephalosporins (e.g., cefazolin) or amoxicillin/
clavulanate was used most often for surgical
prophylaxis, and 47% of organisms from
Electronic supplementary material The online
version of this article (doi:10.1007/s40121-014-0048-4)
contains supplementary material, which is available to
authorized users.
K. V. I. Rolston (&)  L. Nesher
Department of Infectious Diseases, Infection
Control and Employee Health, Unit 1460, The
University of Texas MD Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, TX, USA
e-mail: krolston@mdanderson.org
J. T. Tarrand
Department of Laboratory Medicine, Infection
Control and Employee Health, Unit 1460, The
University of Texas MD Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, TX, USA
Infect Dis Ther (2014) 3:245–256
DOI 10.1007/s40121-014-0048-4
monomicrobial infections (MRSA, P. aeruginosa)
were resistant to them. A similar resistance
pattern was observed in polymicrobial
infections.
Conclusion: Staphylococcus species were isolated
most often from the sites studied. Polymicrobial
infections (42%) and GNB monomicrobial
infections (13%) were relatively frequent
causes of SSIs. Many of these infections were
caused by organisms that are resistant to agents
commonly used for surgical prophylaxis.
Additionally, 65% of staphylococcal isolates
had a vancomycin MIC C1.0 lg/ml, suggesting
the need for alternative therapeutic agents.
Keywords: Cancer; Gram-negative bacteria;
Gram-positive bacteria; Hematologic
malignancies; Surgical site infections
INTRODUCTION
Patients with cancer develop infections
frequently, both as a result of the underlying
malignancy, and its treatment [1]. Whereas
infections in patients with hematologic
malignancies and in recipients of
hematopoietic stem cell transplantation have
been well studied, data on infections in patients
with solid tumors who are not neutropenic are
scarce [2, 3]. Our institution has been
designated a Comprehensive Cancer Center by
the National Cancer Institute, and cares
exclusively for patients with cancer. As part of
our infection control and antimicrobial
stewardship initiatives, we conduct periodic
surveillance studies to determine the most
current epidemiology/microbiology of
infections in our patients [4]. These surveys
help us determine the most appropriate
antimicrobial agents for prophylaxis, empiric
therapy, and targeted therapy for various
patient subgroups at our institution [5].
Specific recommendations are included in
institutional guidelines and pathways, which
are updated periodically.
In contrast to patients with hematologic
malignancies, patients with solid tumors
frequently undergo various diagnostic and
therapeutic surgical procedures, and surgical
site infections (SSIs) are among the most
common infections seen in such patients [6].
Consequently, peri-operative antimicrobial
prophylaxis is administered to the majority of
patients undergoing these procedures. Many of
the agents (e.g., first- or second-generation
cephalosporins) commonly used for
prophylaxis were selected for this indication
several decades ago, and are probably outdated
due to recent epidemiologic changes and
alterations in susceptibility/resistance patterns
globally [7–10]. Additionally, if a postsurgical
infection develops, patients are often given
empiric antimicrobial therapy designed to
provide coverage against anticipated
pathogens, prior to culture results being
available. These empiric regimens are adjusted
once culture results become available. We
recently conducted a survey of the current
microbiology of infections associated with
common surgical procedures performed at our
institution. This information is useful in
determining whether our guidelines for
prophylaxis and empiric therapy are adequate
or need updating. Our findings form the basis of
this report. We did not look at treatment and
outcomes of these patients, since this was
purely a microbiologic survey, and no specific
treatment algorithms were being evaluated.
METHODS
At our institution, all microbiological samples
from clinical sources are submitted to and
processed by a central microbiology
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laboratory. We conducted a retrospective review
of the computerized records of the laboratory
between January 2011 and February 2012 to
identify episodes of infection associated with (1)
breast cancer surgery, (2) thoracic surgery, (3)
craniotomy for brain tumor resection, (4)
percutaneous endoscopic gastrostomy (PEG)
tube insertion, and (5) abdominal/pelvic
surgery. These were chosen because they are
among the most common procedures
performed at our institution. Only patients
with solid tumors were studied and only one
episode of infection per patient was included in
this survey to avoid duplication. Microbial
identifications were performed using
established criteria [11]. Enterobacteriaceae and
most facultative anaerobes were identified using
VITEK 1 system (Bio Merieux, Marcy L’Etoile,
France). For organisms with questionable
identification, 16s ribosomal sequencing was
performed [12]. Susceptibility testing was
performed using the VITEX 1 system using
GPS card 119 and GNS card 132 and 134, or
E-test method for non-fermenters, fastidious
organisms, and the enterococci (AB Biodisk,
Solna, Sweden).
Interpretive Standards for Susceptibilities
were derived from CLSI, M1 00-518, M7-A 7,
and M2-A 10 documents [13]. Our laboratory
reports all isolated organisms and does not
make specific recommendations regarding
their clinical importance, although general
notes indicating whether organisms are likely
to be colonizers or contaminants are included.
We do not routinely perform susceptibility
studies on all organisms isolated from
polymicrobial infections unless specifically
requested by the treating team. Consequently,
susceptibility data were not available for some
isolates from polymicrobial infections. Our
laboratory also does not routinely perform
susceptibility testing on common skin
colonizers such as coagulase-negative
staphylococci and Corynebacterium species
unless they are isolated from concomitant
blood culture specimens.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Prior to conducting this survey




During the study period we identified 368
patients with SSIs. Of these, 143 (39%) were
men and 225 (61%) were women. The age range
of the study patients was 17–81 years. The most
common underlying tumors were breast cancer
(68 patients, 18%), lung cancer (62 patients,
17%), head and neck tumors (61, 17%), brain
tumors (45 patients, 12%), and ovarian cancers
(34 patients, 9%). Since this was a
microbiological survey, it was not possible to
determine the exact number of patients who
received peri-operative antimicrobial
prophylaxis for the surgical procedures they
underwent. However, upon review of
institutional antimicrobial prophylaxis
guidelines/pathways for the procedures
studied, the agents used most often were early
cephalosporins (cefazolin, cefotetan, and
cefoxitin) and amoxicillin/clavulanate. The
microbiological details of these SSIs are
presented below.
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Infections Associated with Breast Cancer
Surgery
A total of 68 cases of SSIs following breast cancer
surgery were identified (Table 1). Of these,
41 episodes (60.3%) were monomicrobial.
Methicillin-susceptible Staphylococcus aureus
(MSSA) accounted for 18 (43.9%) of these
episodes, followed by methicillin-resistant
Staphylococcus aureus (MRSA) with 9 episodes
(22.0%). Other isolated organisms included
coagulase-negative staphylococci (not
routinely identified to species level, but
primarily Staphylococcus epidermidis), beta-
hemolytic Streptococcus species (Groups A and
B), and Pseudomonas aeruginosa. Twenty-seven of
the 68 episodes (39.7%) were polymicrobial.
Staphylococcus species were isolated from all of
these episodes including MSSA from 15 episodes
(55.6%), and MRSA from 12 episodes (44.4%).
Other organisms isolated included coagulase-
negative staphylococci, Corynebacterium species,
beta-hemolytic Streptococcus species (Groups A,
B, and C), Enterococcus species, Escherichia coli,
Citrobacter species, Klebsiella species, Enterobacter
species, Proteus mirabilis and P. aeruginosa
(Table 1).
Infections Associated with Thoracic
Surgery
Ninety-one SSIs were identified in patients
undergoing thoracic surgery. Of these, 58
(63.7%) were monomicrobial and 33 (36.3%)
were polymicrobial. MSSA was isolated most
often (43.1%) from patients with
monomicrobial infections, followed by MRSA
(27.6%) and beta-hemolytic streptococci
(Groups A, B, and G). Other organisms isolated
included coagulase-negative staphylococci,
P. aeruginosa, and E. coli. MRSA was isolated
from 60.6% of episodes of polymicrobial SSIs
following thoracic surgery, and MSSA was
isolated from 48.5% of these episodes. Other
organisms commonly isolated were beta-
hemolytic Streptococcus species, E. coli, other
Enterobacteriaceae, and P. aeruginosa (Table 2).
PEG-tube Insertion Site Infections
A total of 75 episodes of PEG-tube insertion SSIs
were identified during the study period
(Table 3). Of these, 39 episodes (52.0%) were
monomicrobial. Organisms most commonly
isolated were MSSA (28.2%), MRSA (20.5%), P.
aeruginosa (17.9%), Streptococcus species and
Candida species (10.3% each). Thirty-six
episodes (48.0%) were polymicrobial.
Staphylococci were isolated from 33 (91.7%) of
these episodes with MSSA being isolated from
21 (58.3%) and MRSA from 12 (33.3%). Other
common pathogens included P. aeruginosa (17
episodes, 47.2%), E. coli (13 episodes, 36.1%),
other Enterobacteriaceae (16 episodes, 44.4%),
and Streptococcus species (7 episodes, 19.4%).
Candida species were isolated from 18 episodes
but the clinical significance of these isolates was
unclear.
Craniotomy Site Infections
A total of 45 craniotomy site infections were
identified (Table 4). Of these, 28 (62.2%) were
monomicrobial and 17 (37.8%) were
polymicrobial. The most commonly isolated
organisms from monomicrobial infections
were MSSA (53.6%), MRSA (32.1%), and
various Gram-negative rods (14.3%). The most
commonly isolated organisms from
polymicrobial infections were MSSA (11
episodes, 64.7%), MRSA (7 episodes, 41.2%),
and P. aeruginosa (5 episodes, 29.4%).
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Abdominal and Pelvic Wound Infections
A total of 89 episodes of infection associated
with abdominal/pelvic surgery were identified
(Table 5). Of these, 49 (55.1%) were
monomicrobial and 40 (44.9%) were
polymicrobial. The most commonly isolated
organisms from monomicrobial infections
were MSSA (42.9%), MRSA (36.7%), P.
aeruginosa (10.2%), and other enteric Gram-
negative bacteria. The most commonly isolated
organism from polymicrobial infections were
MSSA (26 episodes, 65.0%), MRSA (19 episodes,
47.5%), P. aeruginosa (9 episodes, 22.5%), other
enteric Gram-negative bacteria, Candida species,
and Enterococcus species.
Table 1 Microbiologic details of surgical site infections















Streptococcus species 8 (19.5)
Pseudomonas aeruginosa 2 (4.9)







Klebsiella species 6 (22.2)
Corynebacterium species 2 (7.4)
Streptococcus species 8 (29.6)
Enterococcus species 2 (7.4)
Escherichia coli 9 (33.3)
Proteus mirabilis 5 (18.5)
Enterobacter species 2 (7.4)
Citrobacter species 2 (7.4)




















Streptococcus species 9 (15.5)
Pseudomonas aeruginosa 3 (5.2)
Escherichia coli 1 (1.7)










Corynebacterium species 2 (6.1)
Bacillus species 2 (6.1)
Streptococcus species 11 (33.3)
Escherichia coli 8 (24.2)
Pseudomonas aeruginosa 7 (21.2)
Other Enterobacteriaceae 11 (33.3)
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Susceptibility Data
Susceptibility data are shown in Table 6. When
combining data from all of the infection sites,
90 of the 215 monomicrobial infections (41.8%)
were caused by MSSA. All these organisms were
susceptible to vancomycin. However, 54 of
these (60.0%) had a vancomycin minimal
inhibitory concentration (MIC) C1.0 lg/ml.
Sixty (27.9%) monomicrobial infections were
caused by MRSA, with all isolates being
vancomycin susceptible, but with 44 isolates
(73.3%) having a vancomycin MIC C1.0 lg/ml.
All staphylococcal isolates were susceptible to
linezolid and trimethoprim/sulfamethoxazole,
and [90% were susceptible to rifampin and
minocycline. A limited number of isolates were
tested against daptomycin, and all were
susceptible. Three of the 16 (18.8%) P.
aeruginosa isolates were quinolone resistant,
with one being multidrug resistant (i.e.,
Table 3 Microbiologic details of PEG-tube insertion site















Pseudomonas aeruginosa 7 (17.9)
Streptococcus species 4 (10.3)
Serratia marcescens 3 (7.7)
Candida species 4 (10.3)







Streptococcus species 7 (19.4)
Enterococcus species 8 (22.2)
Escherichia coli 13 (36.1)
Other Enterobacteriaceae 16 (44.4)
Pseudomonas aeruginosa 17 (47.2)
Stenotrophomonas maltophilia 2 (5.6)
Acinetobacter species 1 (2.8)
Candida species 18 (50.0)
























Pseudomonas aeruginosa 5 (29.4)
Enterobacteriaceae 4 (23.5)
Streptococcus species 3 (17.6)
Bacillus species 2 (11.8)
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resistant to at least three classes of antimicrobial
agents expected to be active against it).
As mentioned previously, not all isolates
from polymicrobial infections were tested for
antimicrobial susceptibility. As with
monomicrobial infections, all 73 MSSA isolates
were susceptible to vancomycin, but 51 of these
(69.9%) had a vancomycin MIC C1.0 lg/ml. Of
the 50 MRSA strains isolated from
polymicrobial infections, 29 (58.0%) had
vancomycin MICs C1.0 lg/ml, although all of
Table 5 Microbiologic details of wound infections















Enterococcus species 1 (2.0)
Candida species 1 (2.0)











Escherichia coli 19 (47.5)
Pseudomonas aeruginosa 9 (22.5)
Enterococcus species 9 (22.5)
Candida species 9 (22.5)







Table 6 Antimicrobial susceptibility of organisms
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these were vancomycin susceptible. All
staphylococcal isolates were susceptible to
linezolid and trimethoprim/sulfamethoxazole,
and [95.0% were susceptible to rifampin and
minocycline. Of the 39 P. aeruginosa isolates
tested, 7 (17.9%) were quinolone resistant and 3
(7.7%) were multidrug resistant. Among the
other Gram-negative bacilli tested, most were
relatively susceptible except for Achromobacter
spp. and Stenotrophomonas maltophilia, both of
which were multidrug resistant. Of the 19
enterococcal isolates tested, 3 (15.8%) were
vancomycin resistant, but all were susceptible
to daptomycin and linezolid. Overall, 46.5% of
bacterial organisms isolated from
monomicrobial SSIs (predominantly MRSA and
P. aeruginosa) were resistant to amoxicillin/
clavulanate and the first- and second-
generation cephalosporins (Fig. 1). Although
not all organisms isolated from polymicrobial
infections were available for susceptibility
testing, a similar pattern was noticed among
those that were.
DISCUSSION
SSIs are the most common post-operative
complications associated with surgical
procedures. They are defined as infections that
occur within 30 days of a surgical procedure (or
within 1 year, if an implant has been left in
place) affecting either the incision or deep tissue
at the operative site [14, 15]. The development
of SSIs can lead to prolonged hospital stay with
increased costs, medical comorbidity,
psychological and emotional trauma, poor
cosmetic results, and occasionally, a delay in
post-operative adjuvant therapies [16]. Both
Fig. 1 Details of monomicrobial surgical site infections
including the number of isolates resistant to prophylactic
agents. MSSA methicillin-susceptible Staphylococcus aureus,
MRSA methicillin-resistant Staphylococcus aureus, CoNS
coagulase-negative staphylococci, GNB Gram-negative
bacilli
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patient-related and procedure-related factors
influence the risk of SSIs, and a recent analysis
concluded that patient-related factors (e.g.,
advanced age, diabetes mellitus, and low
serum albumin indicative of poor nutritional
status, smoking, pre-existing colonization/
infection with S. aureus) were predominant
[17]. Many of these factors are present in
patients with cancer. Additionally, surgical
incisions in previously irradiated areas are
more likely to have poor or delayed healing,
and develop secondary infections.
Consequently, infection prevention is
important and antimicrobial prophylaxis is
recommended for most of these surgical
procedures [7–9, 18, 19]. The agents
commonly used for prophylaxis (e.g., first- or
second-generation cephalosporins; amoxicillin/
clavulanate) were selected several decades ago,
based on microbiologic data available then [20].
In the past, methicillin-susceptible S. aureus
and, to a lesser extent, beta-hemolytic
streptococci were the predominant organisms
causing SSIs [21]. Data from our study provide
confirmation that Gram-positive bacteria
remain the most frequently isolated pathogens
in SSIs in cancer patients, regardless of the
specific site of infection. Of the 157
monomicrobial infections, 129 (82%) were
caused by Gram-positive pathogens. However,
streptococci accounted for only 8% (12 of 157)
of these infections, possibly because current
prophylactic regimens are still effective against
these organisms. In contrast, staphylococci
accounted for 109 of 157 episodes of
monomicrobial infections (70%), suggesting
that prophylaxis was not particularly effective.
Of concern is the fact that 40% of S. aureus
isolates were methicillin resistant, and that 67%
of staphylococcal isolates had a vancomycin
MIC C1.0 lg/ml. Although there is some
variability with susceptibility test results using
different methods (E-test, which we used,
usually gives higher MIC values than other
methods), such organisms have been shown to
cause infections that respond slowly, or not at
all, to therapy with vancomycin [22–24]. Also of
concern is the fact that such isolates are now
almost as common among MSSA as they are
among MRSA strains. These data have
therapeutic implications and suggest that
vancomycin might no longer be the agent of
choice for the treatment of staphylococcal SSIs
at our institution.
We were surprised to find that Gram-
negative bacilli caused a substantial proportion
(23 of 157 episodes, 15%) of monomicrobial
infections, with P. aeruginosa (16 of 23 episodes,
70%) being the predominant pathogen.
Although not frequent, the isolation of
multidrug-resistant P. aeruginosa and other
Gram-negative organisms is of some concern.
While this epidemiologic shift does not justify
the administration of prophylaxis with broad-
spectrum and/or anti-pseudomonal agents on a
routine basis to all patients undergoing surgical
procedures (particularly since institutional/
geographic differences do occur), it should not
be ignored. Other investigators have also
reported an increase in the frequency of SSIs
caused by Gram-negative organisms (49% in
one study), and have suggested that alternatives
to cefazolin or similar agents, be considered for
prophylaxis [25, 26]. We believe that individual
institutions performing substantial numbers of
these surgical procedures should generate their
own data, and assess their own clinical needs.
Since many of these procedures are elective,
determining the presence of colonization with
problem organisms such as MRSA or P.
aeruginosa prior to surgery, and administering
targeted prophylaxis to patients who are
colonized, might be one approach in this
setting. Based on our data, and on some
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clinical experience, we have instituted a change
in our clinical practice in our breast cancer
cohort by providing empiric coverage against
Gram-negative organisms including P.
aeruginosa until microbiologic data become
available. We strongly recommend
discontinuation of anti-pseudomonal coverage
if subsequent cultures do not confirm it as a
pathogen.
We were even more surprised to find a high
proportion of polymicrobial infections at all
surgical sites studied. The combined frequency
of polymicrobial infections was 43.3%, ranging
from a low of 37.7% for craniotomy site
infections, to a high of 48% for PEG-tube
insertion site infections. We realize that when
multiple pathogens are isolated, it is often not
possible to determine the exact role played by
individual organisms in the pathogenesis of
polymicrobial infections. Nevertheless, it is
striking that the organisms isolated most
frequently from such infections (Staphylococcus
species including MRSA and P. aeruginosa) are
the same as those isolated most frequently from
monomicrobial infections, probably reflecting
the inadequacy of the agents used for
prophylaxis as well. We have documented an
increase in the overall frequency of
polymicrobial infections in cancer patients,
including patients with and without
neutropenia [27]. Based on our current
microbiologic data and guidelines provided by
our antimicrobial stewardship initiative and on
some recent clinical experience, we have
instituted changes in our clinical practice by
providing broad-spectrum empiric therapy,
followed by de-escalation if possible, once
microbiologic data become available [28]. We
recommend this approach in other institutions
that are experiencing epidemiologic changes
similar to ours.
CONCLUSION
Although Gram-positive bacteria continue to
be isolated more frequently from SSIs than
Gram-negative bacteria, our data from cancer
patients indicate that there have been
significant changes in the epidemiology of
these infections in recent times. The overall
frequency of monomicrobial infections has
declined, and the incidence of polymicrobial
infections has increased considerably.
The frequency of streptococci-causing
monomicrobial infections has also declined. In
contrast, the frequency of MRSA isolation has
increased substantially. Additionally, we have
noticed an MIC creep with reference to
vancomycin, with the majority of current
isolates of MSSA and MRSA having
vancomycin MICs C1.0 lg/ml. The frequency
of Gram-negative bacilli causing
monomicrobial SSIs has also increased with P.
aeruginosa being the predominant pathogen.
Staphylococci and P. aeruginosa are also the
most common pathogens isolated from
polymicrobial infections. Approximately, half
of the organisms that were available for
susceptibility testing were resistant to agents
that are commonly used for surgical
prophylaxis (cephalosporins, amoxicillin/
clavulanate). These findings have led us to re-
evaluate our prophylactic and therapeutic
options and strategies. We believe that these
epidemiologic changes are widespread and
encourage other institutions to conduct
similar investigations.
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